Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Ninlaro Ixazomib Multiple Myeloma Do not reimburse Complete
Nitisinone nitisinone Hereditary tyrosinemia type 1 Reimburse with clinical criteria and/or conditions Complete
Norprolac Quinagolide hydrochloride Hyperprolactinemia Do not list Complete
Norprolac Quinagolide hydrochloride Hyperprolactinemia List with clinical criteria and/or conditions Complete
NovoMix 30 Insulin aspart/insulin aspart protamine Diabetes mellitus Do not list Complete
Nplate Romiplostim Chronic immune (idiopathic) thrombocytopenic purpura (ITP) Do not list Complete
Nubeqa darolutamide Metastatic castration-sensitive prostate cancer Reimburse with clinical criteria and/or conditions Complete
Nubeqa Darolutamide non-metastatic castration resistant prostate cancer (nmCRPC) Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Severe chronic rhinosinusitis with nasal polyps Reimburse with clinical criteria and/or conditions Complete
Nucala mepolizumab Asthma, severe eosinophilic Reimburse with clinical criteria and/or conditions Complete